Steady state bone marrow (BM) is the preferred hematopoietic stem cell (HSC) source for gene therapy in sickle cell disease (SCD) due to the recognized risk of vaso-occlusive crisis during granulocyte colony–stimulating factor mobilization. We previously established clinically relevant HSC gene transfer in the rhesus model following transplantation of mobilized peripheral blood (PB) CD34+ cells transduced with lentiviral vectors. In this study, we examined steady state bone marrow (BM) in the rhesus competitive repopulation model and demonstrate similar gene marking in vitro and in vivo, as compared with mobilized PB CD34+ cells. We then evaluated PB and steady state BM in subjects with SCD and observed a higher frequency of CD34+ cells when compared with controls, likely due to enhanced hematopoiesis. However, CD34+ cell counts were reduced in both the PB and BM in patients treated with hydroxyurea, and hydroxyurea treatment strongly inhibited iPS cell generation from SCD subjects. Our data support that steady state BM is a useful HSC source for SCD gene therapy with similar transduction. The lower CD34+ percentages observed with hydroxyurea treatment warrants withholding hydroxyurea temporarily prior to harvesting HSCs. Our results are important for the design of gene targeting strategies for SCD.
Get full access to this article
View all access options for this article.
References
1.
CharacheS, TerrinML, MooreRD, et al.Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med, 1995; 332:1317–1322.
2.
FitzhughCD, HsiehMM, AllenD, et al.Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia. PLoS One, 2015; 10:e0141706.
3.
HsiehMM, KangEM, FitzhughCD, et al.Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med, 2009; 361:2309–2317.
4.
HsiehMM, FitzhughCD, WeitzelRP, et al.Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA, 2014; 312:48–56.
5.
WaltersMC, PatienceM, LeisenringW, et al.Bone marrow transplantation for sickle cell disease. N Engl J Med, 1996; 335:369–376.
6.
Cavazzana-CalvoM, PayenE, NegreO, et al.Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature, 2010; 467:318–322.
7.
ZouJ, MaliP, HuangX, DoweySN, ChengL. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood, 2011; 118:4599–4608.
8.
AiutiA, CattaneoF, GalimbertiS, et al.Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med, 2009; 360:447–458.
9.
AiutiA, SlavinS, AkerM, et al.Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 2002; 296:2410–2413.
10.
Hacein-Bey-AbinaS, von KalleC, SchmidtM, et al.A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med, 2003; 348:255–256.
11.
OttMG, SchmidtM, SchwarzwaelderK, et al.Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med, 2006; 12:401–409.
12.
SchwarzwaelderK, HoweSJ, SchmidtM, et al.Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest, 2007; 117:2241–2249.
13.
SmithEC, OrkinSH. Hemoglobin genetics: recent contributions of GWAS and gene editing. Human molecular genetics, 2016; 25:R99–r105.
14.
UrbinatiF, HargrovePW, GeigerS, et al.Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+ cells. Exp Hematol, 2015; 43:346–351.
15.
HobanMD, CostGJ, MendelMC, et al.Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood, 2015; 125:2597–2604.
16.
HobanMD, LumaquinD, KuoCY, et al.CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells. Mol Ther, 2016; 24:1561–1569.
17.
HannaJ, WernigM, MarkoulakiS, et al.Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science, 2007; 318:1920–1923.
18.
FitzhughCD, HsiehMM, BolanCD, SaenzC, TisdaleJF. Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?. Cytotherapy, 2009; 11:464–471.
19.
UchidaN, HargrovePW, LapCJ, et al.High-efficiency transduction of rhesus hematopoietic repopulating cells by a modified HIV1-based lentiviral vector. Mol Ther, 2012; 20:1882–1892.
20.
UchidaN, WashingtonKN, HayakawaJ, et al.Development of a human immunodeficiency virus type 1-based lentiviral vector that allows efficient transduction of both human and rhesus blood cells. J Virol, 2009; 83:9854–9862.
21.
UchidaN, BonifacinoA, KrouseAE, et al.Accelerated lymphocyte reconstitution and long-term recovery after transplantation of lentiviral-transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor. Exp Hematol, 2011; 39:795–805.
22.
UchidaN, HsiehMM, WashingtonKN, TisdaleJF. Efficient transduction of human hematopoietic repopulating cells with a chimeric HIV1-based vector including SIV capsid. Exp Hematol, 2013; 41:779–788 e771.
23.
UchidaN, EvansME, HsiehMM, et al.Integration-specific in vitro evaluation of lentivirally transduced rhesus CD34(+) cells correlates with in vivo vector copy number. Mol Ther Nucleic Acids, 2013; 2:e122.
24.
UchidaN, HanawaH, DanK, InokuchiK, ShimadaT. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector. J Nippon Med Sch, 2009; 76:134–147.
UchidaN, Haro-MoraJJ, FujitaA, et al.Efficient generation of β-globin-expressing erythroid cells using stromal cell-derived induced pluripotent stem cells from patients with sickle cell disease. Stem Cells, 2016:n/a-n/a.
27.
HemattiP, TuchmanS, LarochelleA, MetzgerME, DonahueRE, TisdaleJF. Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates. Stem Cells, 2004; 22:1062–1069.
28.
MayC, RivellaS, CallegariJ, et al.Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature, 2000; 406:82–86.
29.
PawliukR, WestermanKA, FabryME, et al.Correction of sickle cell disease in transgenic mouse models by gene therapy. Science, 2001; 294:2368–2371.
30.
Hacein-Bey-AbinaS, Von KalleC, SchmidtM, et al.LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 2003; 302:415–419.
31.
EvansME, KumkhaekC, HsiehMM, DonahueRE, TisdaleJF, UchidaN. TRIM5alpha variations influence transduction efficiency with lentiviral vectors in both human and rhesus CD34(+) cells in vitro and in vivo. Mol Ther, 2014; 22:348–358.
32.
LuckL, ZengL, HitiAL, WeinbergKI, MalikP. Human CD34(+) and CD34(+)CD38(-) hematopoietic progenitors in sickle cell disease differ phenotypically and functionally from normal and suggest distinct subpopulations that generate F cells. Exp Hematol, 2004; 32:483–493.
33.
DedeepiyaVD, RaoYY, JayakrishnanGA, et al.Index of CD34+ Cells and Mononuclear cells in the bone marrow of spinal cord injury patients of different age groups: a comparative analysis. Bone Marrow Res, 2012; 2012:787414.
34.
KanterJ, WaltersMC, HsiehMM, et al.Interim results from a Phase 1/2 clinical study of lentiglobin gene therapy for severe sickle cell disease. Blood, 2016; 128:1176–1176.
35.
YannakiE, PapayannopoulouT, JonlinE, et al.Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther, 2012; 20:230–238.
36.
RibeilJA, Hacein-Bey-AbinaS, PayenE, et al.Gene Therapy in a patient with sickle cell disease. N Engl J Med, 2017; 376:848–855.
37.
AnderliniP, RizzoJD, NugentML, SchmitzN, ChamplinRE, HorowitzMM. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant, 2001; 27:689–692.
38.
LaneTA. Allogeneic marrow reconstitution using peripheral blood stem cells: the dawn of a new era. Transfusion, 1996; 36:585–589.
LilesWC, BroxmeyerHE, RodgerE, et al.Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood, 2003; 102:2728–2730.
42.
BroxmeyerHE, OrschellCM, ClappDW, et al.Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med, 2005; 201:1307–1318.
43.
DevineSM, VijR, RettigM, et al.Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood, 2008; 112:990–998.
44.
HendrixCW, CollierAC, LedermanMM, et al.Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr, 2004; 37:1253–1262.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
